The estimated Net Worth of Jereme M Sylvain is at least 12.2 百万$ dollars as of 9 September 2024. Mr. Sylvain owns over 746 units of Dexcom Inc stock worth over 5,770,241$ and over the last 8 years he sold DXCM stock worth over 6,471,383$. In addition, he makes 0$ as Senior Vice President - Finance、 Chief Accounting Officer at Dexcom Inc.
Sign up
Mr. Sylvain DXCM stock SEC Form 4 insiders trading
Jereme has made over 25 trades of the Dexcom Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 746 units of DXCM stock worth 51,586$ on 9 September 2024.
The largest trade he's ever made was selling 11,661 units of Dexcom Inc stock on 12 March 2024 worth over 1,567,355$. On average, Jereme trades about 1,140 units every 79 days since 2017. As of 9 September 2024 he still owns at least 84,274 units of Dexcom Inc stock.
You can see the complete history of Mr. Sylvain stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jereme Sylvain biography
Jereme M. Sylvain serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. He has served as our Vice President, Finance and Corporate Controller and was promoted to Senior Vice President, Finance and Chief Accounting Officer, effective March 9, 2020. Prior to joining DexCom, Mr. Sylvain held various positions at NuVasive, Inc., including Vice President, Corporate Controller and Chief Accounting Officer from August 2016 to September 2018 and Vice President, Corporate Controller from March 2014 to August 2016. Earlier in his career, he worked for Thermo Fisher Scientific, from February 2014 to March 2014, following its acquisition of Life Technologies Corporation, and Life Technologies and its predecessor, Invitrogen Corporation, from July 2007 to February 2014. Prior to joining Invitrogen, Mr. Sylvain worked for the public accounting firm Ernst & Young LLP. Mr. Sylvain obtained his Certified Public Accounting license after receiving a B.A. in Finance from Arizona State University and a M.S. in Accountancy from the University of Notre Dame.
How old is Jereme Sylvain?
Jereme Sylvain is 40, he's been the Senior Vice President - Finance、 Chief Accounting Officer of Dexcom Inc since 2020. There are 28 older and 1 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
What's Jereme Sylvain's mailing address?
Jereme's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Insiders trading at Dexcom Inc
Over the last 20 years, insiders at Dexcom Inc have traded over 724,717,982$ worth of Dexcom Inc stock and bought 165,450 units worth 3,489,100$ . The most active insiders traders include Sean Carney、Kim D Blickenstaff、Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of 892,438$. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth 29,458$.
What does Dexcom Inc do?
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
What does Dexcom Inc's logo look like?
Complete history of Mr. Sylvain stock trades at Dexcom Inc、Nuvasive Inc
Dexcom Inc executives and stock owners
Dexcom Inc executives and other stock owners filed with the SEC include:
-
Kevin Sayer,
Chairman of the Board, President, Chief Executive Officer -
Quentin Blackford,
Chief Financial Officer, Chief Operating Officer -
Richard Doubleday,
Executive Vice President, Chief Commercial Officer -
Andrew Balo,
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development -
Steven Pacelli,
Executive Vice President - Strategy and Corporate Development -
Donald Abbey,
Executive Vice President - Quality and Regulatory Affairs -
Kevin Ronald Sayer,
Exec. Chairman, CEO & Pres -
Jacob Steven Leach,
Exec. VP & CTO -
Bridgette Heller,
Independent Director -
Mark Foletta,
Lead Independent Director -
Eric Topol,
Independent Director -
Jay Skyler,
Independent Director -
Nicholas Augustinos,
Independent Director -
Steven Altman,
Independent Director -
Barbara Kahn,
Independent Director -
Richard Collins,
Independent Director -
Kyle Malady,
Independent Director -
Karen Dahut,
Independent Director -
Shelly Selvaraj,
Senior Vice President - Information Technology -
Jeffrey Moy,
Senior Vice President - Operations -
Jereme Sylvain,
Senior Vice President - Finance, Chief Accounting Officer -
Patrick Murphy,
Executive Vice President, Chief Legal Officer -
Jake Leach,
Executive Vice President, Chief Technology Officer -
Shelly Ramasamy Selvaraj,
Sr. VP of Information Technology -
Donald M. Abbey,
Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs -
Steven R. Pacelli,
Exec. VP & MD of Dexcom Ventures -
Andrew K. Balo,
Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. -
Sadie M. Stern,
Exec. VP & Chief HR Officer -
Chad M. Patterson,
Exec. VP of Global Marketing -
Sean Christensen,
Director of Corp. Affairs & Head of Investor Relations -
Jereme M. Sylvain,
Exec. VP, CFO & Chief Accounting Officer -
John Lister,
VP, Legal Affairs -
Terrance H Gregg,
Director -
Jess Roper,
VP, CFO -
Jorge A Valdes,
Vice President of Engineering -
Girish Naganathan,
EVP Chief Technology Officer -
Heather S Ace,
SVP Human Resources -
Kevin M Sun,
VP, Corp Controller & Treasury -
Jonathan T Md Lord,
Director -
Glen D Nelson,
Director -
Peter Gerhardsson,
VP, Int'l Business Development -
David Carner,
VP, Quality Assurance -
Laura Johnson,
V.P., Intellectual Property -
Martin Doordan,
Director -
Sean Carney,
Director -
John Riolo,
VP of Quality Assurance -
Claudia Graham,
VP, Marketing -
Donald A Lucas,
Director -
Donald L Lucas,
Director -
Mark Brister,
VP, Advanced Development Teams -
Richard Yang,
V.P., Strategic Affairs -
James H Brauker,
VP, Research & Development -
Rodney L Kellogg,
Vice President of Sales -
Andrew P Rasdal,
President and CEO -
Steven J Kemper,
Chief Financial Officer -
Kim D Blickenstaff,
Director -
Tae Andrews,
Vice President of Marketing -
Paul Travelers Companies In...,
-
Pincus Private Equity Viii ...,
-
Brenton Karl Ahrens,
Director -
Nancy Sfog City Management ...,
-
Equity Partners Ii Llccanaa...,
-
Paul Travelers Companies In...,
-
Eric A Charmers Landing Llc...,
-
Scott Lwindamere Llcwindame...,
-
Equity Partners Ii Llc Waub...,
-
Teri L Lawver,
EVP Chief Commercial Officer -
Paul R Flynn,
EVP Global Revenue -
Matthew Vincent Dolan,
EVP Strategy and Corporate Dev -
Sumi Shrishrimal,
SVP Chief Risk Officer -
Chad Patterson,
EVP Global Marketing -
Barry J. Regan,
EVP Operations -
Jacob Steven Leach,
EVP, Chief Operating Officer -
Rimma Driscoll,
Director -
Michael Jon Brown,
EVP, Chief Legal Officer -
Sadie Stern,
EVP, Chief HR Officer